Combining xenon and mild therapeutic hypothermia preserves neurological function after prolonged cardiac arrest in pigs

Crit Care Med. 2012 Apr;40(4):1297-303. doi: 10.1097/CCM.0b013e31823c8ce7.

Abstract

Objective: Despite the introduction of mild therapeutic hypothermia into postcardiac arrest care, cerebral and myocardial injuries represent the limiting factors for survival after cardiac arrest. Administering xenon may confer an additional neuroprotective effect after successful cardiopulmonary resuscitation due to its ability to stabilize cellular calcium homeostasis via N-methyl-D-aspartate-receptor antagonism.

Design: In a porcine model, we evaluated effects of xenon treatment in addition to therapeutic hypothermia on neuropathologic and functional outcomes after cardiopulmonary resuscitation.

Setting: Prospective, randomized, laboratory animal study.

Subjects: Fifteen male pigs.

Interventions: Following 10 mins of cardiac arrest and 6 mins of cardiopulmonary resuscitation, ten pigs were randomized to receive either mild therapeutic hypothermia (33°C for 16 hrs) or mild therapeutic hypothermia 1 xenon (70% for 1 hr). Five animals served as normothermic controls.

Measurements and main results: Gross hemodynamic variables were measured using right-heart catheterization. Neurocognitive performance was evaluated for 5 days after cardiopulmonary resuscitation using a neurologic deficit score before the brains were harvested for histopathological analysis. All animals survived the observation period in the mild therapeutic hypothermia 1 xenon group while one animal in each of the other two groups died. Mild therapeutic hypothermia 1 xenon preserved cardiac output during the induction of mild therapeutic hypothermia significantly better than did mild therapeutic hypothermia alone (4.6 6 0.6 L/min vs. 3.2 6 1.6 L/min, p # .05). Both treatment groups showed significantly fewer necrotic lesions in the cerebral cortex, caudate nucleus, putamen, and in hippocampal sectors CA1 and CA3/4. However, only the combination of mild therapeutic hypothermia and xenon resulted in reduced astrogliosis in the CA1 sector and diminished microgliosis and perivascular inflammation in the putamen. Clinically, only the mild therapeutic hypothermia 1 xenon-treated animals showed significantly improved neurologic deficit scores over time (day 1 = 59.0 6 27.0 vs. day 5 = 4.0 6 5.5, p ø .05) as well as in comparison to the untreated controls on days 3 through 5 after cardiopulmonary resuscitation.

Conclusions: These results demonstrate that even a short exposure to xenon during induction of mild therapeutic hypothermia results in significant improvements in functional recovery and ameliorated myocardial dysfunction.

Trial registration: ClinicalTrials.gov NCT01262729.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Animals
  • Brain / drug effects
  • Brain / pathology
  • Brain / physiopathology
  • Cardiopulmonary Resuscitation / methods
  • Disease Models, Animal
  • Heart Arrest / drug therapy
  • Heart Arrest / pathology
  • Heart Arrest / therapy*
  • Hypothermia, Induced / methods*
  • Hypoxia, Brain / drug therapy
  • Hypoxia, Brain / etiology
  • Hypoxia, Brain / pathology
  • Hypoxia, Brain / physiopathology
  • Hypoxia, Brain / therapy*
  • Male
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Swine
  • Xenon / administration & dosage
  • Xenon / therapeutic use*

Substances

  • Neuroprotective Agents
  • Xenon

Associated data

  • ClinicalTrials.gov/NCT01262729